TY  - JOUR 
AU  - Dueñas-Gutiérrez, C.
AU  - Buzón, L.
AU  - Pedrero-Tomé, R.
AU  - Iribarren, J.A.
AU  - De los Santos, I.
AU  - De la Fuente, S.
AU  - Pousada Fernández, Guillermo
AU  - Moran, M.A.
AU  - Moreno, E.
AU  - Ferreira, E.
AU  - Gómez, J.
AU  - Troya, J.
PY  - 2023
SN  - 1999-4915
UR  - http://hdl.handle.net/20.500.11940/21424
AB  - Background: The high effectiveness and safety of the two-drug (2DRs) strategy using dolutegravir (DTG) plus lamivudine (3TC) have led to international guidelines recommending their use for treatment-naive HIV patients. In virologically suppressed...
LA  - eng
KW  - Humans
KW  - Lamivudine
KW  - HIV Infections
KW  - HIV-1
KW  - Anti-HIV Agents
KW  - Retrospective Studies
KW  - Rilpivirine
KW  - Heterocyclic Compounds, 3-Ring
KW  - HIV Seropositivity
KW  - Drug-Related Side Effects and Adverse Reactions
TI  - Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV
DO  - 10.3390/v15040936
T2  - Viruses
KW  - AS Pontevedra
KW  - CHUP
VL  - 15
ER  -